Unless there are contraindications to the use of aspirin, aspirin should be used to treat
patients with acute myocardial infarction (MI) and continued indefinitely to decrease vascular …

Antiplatelet therapy is universally recommended for the prevention of recurrent events in
patients with noncardioembolic ischaemic stroke or transient ischaemic attack (TIA), acute …

In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or mortality
Page 1 In CV disease, clopidogrel reduces nonfatal MI and MACE vs. aspirin but not stroke or …

Objectives Whether clopidogrel should be added to aspirin for stroke prevention remained
controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to …

Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of
subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial …

Objectives: The goal of this study was to investigate the differential efficacy of clopidogrel or
aspirin monotherapy according to smoking status in patients with atherosclerotic vascular …

OBJECTIVE: To review the literature assessing dual antiplatelet therapy with aspirin and
clopidogrel and subsequently provide evidence-based recommendations for appropriate …

Background Despite the use of aspirin, there is still a risk of ischaemic events after
percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to …

BACKGROUND: Clopidogrel is a new antiplatelet agent with potent activity as a platelet
ADP receptor antagonist. CAPRIE compared the long-term benefits of clopidogrel (75 mg …

Based on recent results with glycoprotein IIb/IIIa inhibitors and low molecular weight heparin
having a greater relative benefit in higher risk groups, 1, 2 we hypothesized that acute …